Origami Therapeutics Inks Global Licensing Deal With French Pharma Giant Ipsen

San Diego-based Origami Therapeutics has signed a global licensing agreement with French pharmaceutical company Ipsen for its lead neurodegeneration drug candidate, marking another major deal for the region’s biotech sector.

The deal gives Ipsen exclusive worldwide rights to develop and commercialize Origami’s compound, which targets a novel pathway in neurodegenerative diseases including Alzheimer’s and Parkinson’s. Financial terms include an undisclosed upfront payment plus development and commercial milestone payments that could total several hundred million dollars.

Why It Matters

Neurodegeneration remains one of the most challenging areas in drug development, with a failure rate exceeding 99% for Alzheimer’s candidates in clinical trials. Origami’s approach targets a different biological mechanism than the amyloid-focused drugs that have dominated the field, potentially offering an alternative for patients who don’t respond to existing treatments.

“This partnership validates our science and gives us the resources to advance this program through global clinical development,” said Origami CEO Dr. Brian Bhatt in a statement.

San Diego Biotech Momentum

The Origami deal, combined with UCB’s $2.2 billion acquisition of Candid Therapeutics announced the same week, underscores a hot streak for San Diego biotech dealmaking in 2026. The region’s life sciences sector continues to attract global pharmaceutical interest, driven by strong academic research pipelines at UC San Diego and Scripps Research, and a deep talent pool of experienced biotech executives.

Source: Company press releases, SEC filings, industry analyst coverage.